Ailux Biologics, A Division Of XtalPi, Enters License Agreement With Janssen Biotech To Utilize XtalFold AI Platform For Biologics Discovery And Engineering
Portfolio Pulse from Benzinga Newsdesk
Ailux Biologics, a division of XtalPi, has entered a license agreement with Janssen Biotech to use the XtalFold AI platform for biologics discovery and engineering. The platform has been validated in over 30 programs, aiding in antigen design, epitope identification, and bispecifics design.
October 10, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janssen Biotech, part of Johnson & Johnson, has partnered with Ailux Biologics to use the XtalFold AI platform, enhancing their capabilities in biologics discovery and engineering.
The partnership with Ailux Biologics to use the XtalFold AI platform could enhance Janssen Biotech's capabilities in biologics discovery, potentially leading to innovative products and strengthening JNJ's position in the biotech sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80